Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

By sjmartinez • October 31, 2024

Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron MS, Nassif ME, Oreziak A, Owens AT, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh SF, Wang A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Sherrid MV, Abraham TP; FOREST-HCM Investigators. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024 Nov 5;84(19):1839-1849. doi: 10.1016/j.jacc.2024.09.002. PMID: 39477631.

Tags: aficamten, cardiac myosin inhibitor, Cardiology/Epi, Cedars Sinai DoM, obstructive hypertrophic cardiomyopathy, Publications, standard-of-care medications

Diabetic Cardiomyopathy: What Clinicians Should Know

Smati H, Qadeer YK, Rodriguez M, Moras E, Fonarow GC, Isaacs SD, Marwick TH, Krittanawong C. Diabetic Cardiomyopathy: What Clinicians Should Know. Am J Med.[...]

Heart Failure With Preserved Ejection Fraction-A Role for Invasive Hemodynamics

Fonarow GC, Udelson JE, Yancy CW. Heart Failure With Preserved Ejection Fraction-A Role for Invasive Hemodynamics. JAMA Cardiol. 2024 Nov 6. doi: 10.1001/jamacardio.2024.3764. Epub ahead[...]

Stakeholder Perspectives on a Heart Failure With Reduced Ejection Fraction Polypill: A Multi-Center Mixed Methods Study

Chen JC, DeJong C, Agarwal M, Hairston AM, Durstenfeld MS, McKay V, Huffman MD, Hsue PY, Agarwal A. Stakeholder Perspectives on a Heart Failure With[...]